Repare Therapeutics Inc. announced the approval of the acquisition of all issued common shares by XenoTherapeutics, Inc.
The special resolution for the Arrangement was approved by a significant majority of Shareholders.
The Arrangement is subject to court approval and expected to be finalized by January 28, 2026.
Shareholder Approval
99.76% of Shareholders voted in favor of the Acquisition by XenoTherapeutics, Inc.
Executive Compensation
99.34% of Shareholders approved the compensation for executive officers related to the Arrangement.
Liquidation Approval
99.75% of Shareholders agreed to voluntary liquidation and dissolution if the Arrangement is terminated.
- The completion of the acquisition will mark a significant milestone in Repare Therapeutics' journey.
- Integrating with XenoTherapeutics, Inc. will potentially open up new avenues for research and development in precision oncology.
The approval of the Acquisition by XenoTherapeutics, Inc. sets the stage for an exciting new chapter in Repare Therapeutics Inc.'s future.